Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 521 to 530 of 2443 total matches.
Cladribine (Mavenclad) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
(PML)
compared to other MS treatments.1-3
Oral fingolimod (Gilenya), teriflunomide (Aubagio ...
The FDA has approved cladribine (Mavenclad – EMD
Serono), a purine antimetabolite, for oral treatment
of adults with relapsing forms of multiple sclerosis
(MS), including relapsing-remitting disease and
active secondary progressive MS (SPMS), who
cannot tolerate or have had an inadequate response
to other drugs indicated for treatment of MS. It is
not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved
for treatment of hairy cell leukemia, has been
used off-label for treatment of MS.
Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
Lett Drugs Ther 2019;
61:99), Table 1 should have included single-ingredient oral
formulations ...
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone (Provera, and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than taking Bijuva, but they cost less and...
Drugs for Smoking Cessation
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
in the US. Smoking cessation often requires
both pharmacotherapy and behavioral support.1,2
NICOTINE REPLACEMENT ...
Smoking tobacco remains the primary preventable
cause of death in the US. Smoking cessation often requires
both pharmacotherapy and behavioral support.
Benzhydrocodone/Acetaminophen (Apadaz) for Pain
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
and
acetaminophen or ibuprofen have been available for
years and are the most abused opioid products in the
US.1 ...
The FDA has approved Apadaz (KemPharm), a short-acting,
fixed-dose combination of benzhydrocodone
and acetaminophen, for short-term management
(≤14 days) of acute pain severe enough to require an
opioid and for which alternative treatment options
are inadequate. Benzhydrocodone is a prodrug of
hydrocodone. Fixed-dose combinations of short-acting
hydrocodone and acetaminophen or ibuprofen
have been available for years and are the most abused
opioid products in the US. Apadaz was developed
under the presumption that inclusion of the inactive
prodrug would reduce the potential for...
Expanded Table: Some Drugs for Smoking Cessation (online only)
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
)
Nicotine transdermal patch –
generic
NicoDerm CQ (GSK)
7, 14, 21 mg/24 hr
patches
1 patch/day ...
View the Expanded Table: Some Drugs for Smoking Cessation
Tafenoquine (Arakoda; Krintafel) for Malaria
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
: ta fen’ oh kwin Arakoda: air’ uh koh’ duh
Krintafel: krin tah fell
Table 1. Primaquine ...
The oral antimalarial tafenoquine succinate, a long-acting
analog of primaquine, has been approved by
the FDA in 2 different strengths. Arakoda (100-mg
tablets; Sixty Degrees) is indicated for the prophylaxis
of malaria in adults. Krintafel (150-mg tablets; GSK) is
indicated for the prevention of relapse (radical cure)
of Plasmodium vivax malaria in patients ≥16 years old
undergoing treatment for acute P. vivax infection.
Colorectal Cancer Screening
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
(polyp) can prevent
cancer from developing.1
WHO SHOULD BE SCREENED — Routine screening for
colorectal ...
Most colorectal cancers arise from localized
adenomatous polyps in a process that may take
10 years or more. Early detection and removal of
a precancerous colonic lesion (polyp) can prevent
cancer from developing.
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
that are chemically similar to endogenous hormones
such as estradiol and progesterone.1 FDA-approved
formulations ...
The FDA has approved Bijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with an intact uterus. The manufacturer is marketing
Bijuva as "the first and only FDA-approved combination
of bio-identical estradiol and bio-identical progesterone
in a single daily oral capsule".
Expanded Table: Drugs for Malaria Prophylaxis (online only)
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
Pediatric
1 adult tab (250/100 mg)
once/day
5-8 kg: ½ ped tab/day (1 ped
tab is 62.5/25 mg)
9-10 kg ...
View the Expanded Table: Drugs for Prophylaxis of Malaria
Correction: Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
Correction: Drugs for Chronic Heart Failure
In our Drugs for Chronic Heart Failure article,1 our ...
In our Drugs for Chronic Heart Failure article,1 our description of the PARADIGM-HF trial comparing the combination of the ARB valsartan and the neprilysin inhibitor sacubitril (Entresto) with the ACE inhibitor enalapril for treatment of heart failure with reduced ejection fraction (HFrEF) characterized the dosage of enalapril as "suboptimal". Some readers have objected to that characterization.The FDA-approved dosage of enalapril for treatment of HFrEF is 2.5-20 mg twice daily. In PARADIGM-HF, the dosage was capped at 10 mg twice daily, a widely used dosage that has been shown to reduce...